benazeprilat and acetonitrile

A simple, specific, and rapid kinetic study of benazepril (BNZ) hydrolysis was developed and validated using HPLC. BNZ was degraded using 0.1 N sodium hydroxide at room temperature to produce benazeprilat, which is an active metabolite of BNZ and acts as an angiotensin-converting enzyme inhibitor. Analysis was carried out using an Athena C18 column (4.6 × 250 mm, 5 µm particle size). The mobile phase consists of a mixture of phosphate buffer (pH 4.5) and acetonitrile (53 + 47, v/v) at a flow rate of 1 mL/min. UV detection was accomplished at 242 nm using moexipril as the internal standard. The method was validated according to International Conference on Harmonization guidelines, and the calibration curve was linear over the range 10-100 µg/mL, with acceptable accuracy and precision. Kinetic profiling of the hydrolysis was shown to follow pseudo-first-order kinetics. The method was applied to the assay of BNZ in combined dosage form with no interference from other ingredients. The obtained results were statistically compared with those of the official method, showing no significant difference.

Topics: Acetonitriles; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Buffers; Calibration; Capsules; Chromatography, High Pressure Liquid; Hydrogen-Ion Concentration; Hydrolysis; Inactivation, Metabolic; Kinetics; Reproducibility of Results; Sodium Hydroxide; Tetrahydroisoquinolines

A sensitive and accurate high-performance liquid chromatography (HPLC) method with ultraviolet (UV) detector was developed and validated for simultaneous determination of benazepril (BZL) and its active metabolite, benazeprilat (BZT), in human plasma. The plasma sample, after spiked with riluzole as an internal standard (IS), was subjected to a solid-phase extraction (SPE) prior to a HPLC analysis. Chromatographic separations were achieved on a Hypersil BDS C(18) (300 mm x 4.6mm, 5 microm). The mobile phase consisted of phosphate buffer (pH 2.6; 10mM) and acetonitrile mixture in a gradient mode. Detection was carried out at a wavelength of 237 nm. The retention times of BZL, BZT and IS were at about 6.2, 15.4 and 16.2 min, respectively. The calibration curve was linear in the range of 20-2000 ng/mL for both BZL and BZT (r(2)>0.997). At three quality control concentrations of 100, 500, and 1500 ng/mL, the intra-day and inter-day relative standard deviation ranged from 2.8 to 8.6% for BZL and from 2.2 to 8.5% for BZT, while the mean absolute percentage error ranged from -7.5 to 6.7% for BZL and from -6.0 to 3.2% for BZT. The limit of detection (LOD) was 10 ng/mL and the limit of quantification (LOQ) was 20 ng/mL for both BZL and BZT in human plasma. The method was successfully applied to bioequivalence evaluation of benazepril hydrochloride formulations in healthy Chinese.

Topics: Acetonitriles; Administration, Oral; Angiotensin-Converting Enzyme Inhibitors; Area Under Curve; Asian People; Benzazepines; Buffers; Calibration; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Drug Stability; Freezing; Humans; Hydrogen-Ion Concentration; Male; Molecular Structure; Phosphates; Reference Standards; Reproducibility of Results; Riluzole; Sensitivity and Specificity; Solid Phase Extraction; Spectrophotometry, Ultraviolet; Tablets; Temperature; Therapeutic Equivalency; Time Factors